Cytokinetics of a human neuroblastoma cell line following treatment with dianhydrogalactitol.
暂无分享,去创建一个
[1] M. Melamed,et al. Luminescence of the solid complexes of acridine orange with RNA. , 2005, Cytometry.
[2] K. Bauer,et al. Total cellular RNA content: correlation between flow cytometry and ultraviolet spectroscopy. , 1980, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[3] M. Melamed,et al. Discrimination of human leukemia subtypes by flow cytometric analysis of cellular DNA and RNA. , 1980, Blood.
[4] T. Fleming,et al. Dianhydrogalactitol and radiation therapy. Treatment of supratentorial glioma. , 1979, JAMA.
[5] D. Deen,et al. Perturbed cell kinetics of 9L rat brain tumor cells following dianhydrogalactitol. , 1978, Cancer treatment reports.
[6] M. Walker,et al. Phase II study of dianhydrogalactitol in malignant glioma. , 1978, Cancer treatment reports.
[7] P. Coulson,et al. Quantitation of cellular deoxyribonucleic acid by flow microfluorometry. , 1977, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[8] S. Barranco,et al. Cell killing, kinetics, and recovery responses induced by 1,2:5,6-dianhydrogalactitol in dividing and nondividiing cells in vitro. , 1977, Journal of the National Cancer Institute.
[9] M. Melamed,et al. Simultaneous staining of ribonucleic and deoxyribonucleic acids in unfixed cells using acridine orange in a flow cytofluorometric system. , 1977, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[10] Levin Va,et al. Dianhydrogalactitol (NSC-132313): pharmacokinetics in normal and tumor-bearing rat brain and antitumor activity against three intracerebral rodent tumors. , 1976 .
[11] M. Melamed,et al. Conformation of RNA in situ as studied by acridine orange staining and automated cytofluorometry. , 1975, Experimental cell research.
[12] S. Das,et al. Human neuroblastoma in nude mice. , 1975, Cancer research.
[13] B. Spengler,et al. Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. , 1973, Cancer research.
[14] Z. Szentirmay,et al. Pharmacologic and antitumor effects of 1,2:5,6-dianhydrogalactitol (NSC-132313). , 1972, Cancer chemotherapy reports.
[15] E. Csanyi,et al. Cross-resistance studies on 1,6-dibromo-dideoxy-D-mannitol(DBM)-resistant Yoshida S.C. sarcoma. , 1967, British Journal of Cancer.
[16] H. Bisel,et al. Phase II studies of dianhydrogalactitol-based combination chemotherapy for recurrent brain tumors. , 1981, Oncology.
[17] P. Rózsa,et al. Dianhydrogalactitol and neural tumors: an in vitro, in vivo preclinical evaluation. , 1980, Cancer treatment reports.
[18] I. Pályi. Survival and phase sensitivity of HeLa cells treated with dianhydrogalactitol (NSC-132313). , 1975, Cancer chemotherapy reports.
[19] L. Németh,et al. Investigation into the correlation of cytostatic activity with the in vitro diepoxide formation on some terminally substituted hexitols. , 1970, Neoplasma.